Researchers at Robarts Research Institute in collaboration with McMaster University are developing an innovative lung imaging method that provides a unique window on asthma that is aimed at guiding and personalizing treatment for Canadians with severe, poorly controlled asthma.
Grace Parraga, PhD, and her research team have developed Magnetic Resonance Imaging (MRI) measurements of the asthmatic airways that show exactly where air moves into the lungs when a patient breathes, and more importantly, where the air cannot go when asthma is not optimally treated and symptoms are not controlled.
According to the Canadian Lung Association and Asthma Canada, asthma, a chronic airways disease, affects approximately three million Canadian adults and children and in 2016, 93 per cent of Canadians with asthma reported they had poor control of their disease.
Two major lung airway abnormalities make it difficult for patients with asthma to breathe: airway inflammation and airway sensitivity to triggers related to airway smooth muscle dysfunction. These often occur together in patients, although sometimes patients have flares that are triggered or dominated by only one of these conditions.
“Canadians with asthma currently undergo tests that do not measure the independent and distinct contributions of airway inflammation and airway sensitivity to triggers that account for their symptoms and need for medication,” said Parraga, Professor at Western’s Schulich School of Medicine & Dentistry and Scientist at Robarts Research Institute.
Now, for the first time, imaging experts at Western – in collaboration with a team at the Firestone Institute for Respiratory Health at McMaster University and St. Joseph’s Healthcare Hamilton – are using two distinct measurements of mucus from the lungs (or sputum) in combination with MRI to quantify the different contributions of both airway inflammation and airway smooth muscle dysfunction in individual patients with severe asthma.
“Airway inflammation can be identified reliably by cell-based measurements of patient sputum and smooth muscle dysfunction can be identified by assessing airway sensitivity to stimuli, tests developed at McMaster University. It is quite important to identify these two separate components, particularly in patients with severe asthma, because the different abnormalities are treated with different therapies,” said Dr. Parameswaran Nair, a Professor of Medicine at McMaster University.
“When MRI is used to directly measure and visualize the contributions of airway inflammation and smooth muscle abnormalities to asthma symptoms, as we did in this study, we can start to consider personalizing therapy for individual patients, which is very exciting because it holds the promise for much better quality of life for patients and lower health care costs,” said Parraga.
The study was funded by the Canadian Respiratory Research Network, which aimed to stimulate collaborations across research disciplines, such as imaging and inflammatory research, and was supported by the post-doctoral fellowship of Sarah Svenningsen, PhD, to conduct this study at Robarts Research Institute in collaboration with the Firestone Institute for Respiratory Health.
Published in this month’s print edition of The American Journal of Respiratory and Critical Care Medicine (https://www.atsjournals.org/doi/abs/10.1164/rccm.201709-1948OC), the study was performed in 27 patients with very severe asthma from across Canada who travelled to both sites to complete the study.
The team is now embarking on studies to utilize this technology developed at Robarts to direct innovative therapies for patients with severe asthma. Lung MRI may help ensure that the right treatment can be delivered to the right asthma patient at the right time in order to abolish asthma symptoms and improve disease control.